With regard to imetelstat which is really first-in-class telomerase inhibitor that’s in the clinic today, we today have 100% ownership of the global rights to the molecule.
We’re going to talk about the fact that there is evidence of potential disease modifying activity in three — at least three of the myeloid malignancies, ETP the — I’m sorry, ET myelofibrosis and myelodysplastic syndrome. We have two ongoing studies which are the subjects of the talks today.
A note for the more commercially-inclined audience, that we were granted Fast Track designation by FDA for treatment of lower risk MDS last year. We have — in regards to future plans, we have — had $185 million in the bank as of 9/30, and that certainly moved us forward into Phase 3.
We plan to build on our existing organizational strengths by adding more experienced development personnel, particularly in hem malignancies. Hot on the trail of that effort, we are planning to begin screening and enrollment for the Phase 3 portion of IMerge by mid-year 2019 after we transition the IND back from Janssen. And we are very much exploring the potential for late-stage development in MF and expect a corporate decision by the end of the third quarter of 2019.
So it’s my pleasure to introduce Dr. John Mascarenhas, as you see he is a very accomplished investigator and clinician in the field and in particular in myelofibrosis. You can see that he did — has a long and distinguished career in both academia and patient care. And he has done quite a bit of translational research in malignant hematology and hematologic malignancies in the development of a variety of different investigator-sponsored clinical trials in patients with myeloproliferative neoplasms and AML.
So as I said he’s going to reprise the discussion of what he gave at ASH this year and he’s also going to speak a little bit about myelofibrosis in general.